US President Donald Trump has signed an executive order to expedite the FDA review process for certain psychedelic drugs, with a particular focus on ibogaine, a compound eyed for treating post-traumatic stress disorder and addiction. Alongside this, the administration announced a $50 million federal investment to advance research into ibogaine’s potential, especially for veterans grappling with trauma.
Ibogaine, derived from a shrub native to Africa, is currently classified as a Schedule I drug in the U.S., placing it alongside substances like heroin due to its perceived high abuse potential and lack of accepted medical use. Despite this, it has shown promise in small studies for addressing depression, anxiety, addiction, and brain trauma. A study published last July by Stanford Medicine involving 30 veterans found that ibogaine, when paired with intravenous magnesium to mitigate heart risks, safely reduced PTSD symptoms, anxiety, and depression—though the absence of a placebo group limits broader conclusions.
The executive order aims to unlock federal funding for more rigorous clinical trials to assess ibogaine’s safety and efficacy. Trump officials emphasized the need to determine whether the drug is a legitimate treatment or merely speculative, with research still in its early stages. Texas has already taken a lead, with Governor Greg Abbott signing a bill last year to allocate $50 million for ibogaine studies, signaling growing state-level interest.
Safety remains a critical hurdle. A 2023 review of 24 studies involving 705 people highlighted ibogaine’s potential to reduce withdrawal symptoms and cravings, but flagged serious cardiac toxicity risks, including fatal heart rhythm disturbances. At least 27 deaths have been linked to the drug, underscoring the urgency for standardized protocols.
Many Americans currently seek ibogaine treatment at unregulated clinics in Mexico or the Caribbean, often without proper heart screenings or monitoring. A ’60 Minutes’ segment last year detailed nine U.S. veterans traveling to a remote village near Puerto Vallarta for a week-long psychedelic retreat to confront intrusive memories, illustrating the lengths to which some go for relief.
Trump’s move comes as scientific evidence remains sparse, with only one double-blind, placebo-controlled randomized clinical trial completed to date. Larger, more advanced trials are just beginning. The administration’s $50 million commitment, paired with the accelerated FDA process, could mark a turning point for ibogaine research by year-end 2026 if trials progress as planned.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
